John Newman
Stock Analyst at Canaccord Genuity
(2.13)
# 2,928
Out of 5,148 analysts
89
Total ratings
44.87%
Success rate
-6.42%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATRA Atara Biotherapeutics | Downgrades: Hold | $25 → $6 | $4.91 | +22.20% | 7 | Jan 13, 2026 | |
| ACET Adicet Bio | Maintains: Buy | $128 → $18 | $7.29 | +146.91% | 7 | Jan 6, 2026 | |
| ACLX Arcellx | Maintains: Buy | $130 | $114.05 | +13.99% | 10 | Dec 8, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $850 → $1,057 | $790.81 | +33.66% | 20 | Dec 4, 2025 | |
| CMPX Compass Therapeutics | Initiates: Buy | $10 | $5.68 | +76.06% | 1 | Dec 3, 2025 | |
| NUVL Nuvalent | Initiates: Buy | $126 | $101.29 | +24.40% | 1 | Nov 12, 2025 | |
| DCTH Delcath Systems | Maintains: Buy | $21 | $8.93 | +135.16% | 2 | Oct 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Buy | $14 → $22 | $8.96 | +145.54% | 10 | Sep 24, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $14 | $2.65 | +428.30% | 3 | Mar 14, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $107.48 | +59.51% | 8 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.40 | +471.43% | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $25 | $5.11 | +389.24% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $43 | $7.60 | +465.79% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.02 | +390.20% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $29.20 | +50.68% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $13.90 | +173.48% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $5.62 | +380.43% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $14.21 | - | 1 | Sep 13, 2017 |
Atara Biotherapeutics
Jan 13, 2026
Downgrades: Hold
Price Target: $25 → $6
Current: $4.91
Upside: +22.20%
Adicet Bio
Jan 6, 2026
Maintains: Buy
Price Target: $128 → $18
Current: $7.29
Upside: +146.91%
Arcellx
Dec 8, 2025
Maintains: Buy
Price Target: $130
Current: $114.05
Upside: +13.99%
Regeneron Pharmaceuticals
Dec 4, 2025
Maintains: Buy
Price Target: $850 → $1,057
Current: $790.81
Upside: +33.66%
Compass Therapeutics
Dec 3, 2025
Initiates: Buy
Price Target: $10
Current: $5.68
Upside: +76.06%
Nuvalent
Nov 12, 2025
Initiates: Buy
Price Target: $126
Current: $101.29
Upside: +24.40%
Delcath Systems
Oct 21, 2025
Maintains: Buy
Price Target: $21
Current: $8.93
Upside: +135.16%
Seres Therapeutics
Sep 24, 2025
Maintains: Buy
Price Target: $14 → $22
Current: $8.96
Upside: +145.54%
Allogene Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $14
Current: $2.65
Upside: +428.30%
BioNTech SE
Mar 11, 2025
Maintains: Buy
Price Target: $171
Current: $107.48
Upside: +59.51%
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $1.40
Upside: +471.43%
Feb 26, 2025
Maintains: Buy
Price Target: $20 → $25
Current: $5.11
Upside: +389.24%
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $7.60
Upside: +465.79%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $1.02
Upside: +390.20%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $29.20
Upside: +50.68%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $13.90
Upside: +173.48%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $5.62
Upside: +380.43%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $14.21
Upside: -